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ABSTRACT 57 
Diet and estrogen influence female visceral obesity by poorly understood effector mechanisms. 58 
Estrogen regulates the aldehyde dehydrogenase-1 family of enzymes (Aldh1A1, A2, and A3) that 59 
converts vitamin A metabolite retinaldehyde (Rald) to retinoic acid (RA). We hypothesized that this 60 
endogenous RA generation mediates sex-specific differences in visceral fat formation. 61 
We identified Aldh1A1 as the major enzyme producing RA during adipogenesis in vitro and in 62 
mouse visceral fat in vivo. In high-fat-fed Aldh1A1−/− female mice compared to male groups, RA 63 
generation in visceral fat was impaired due to decreased Aldh1A2, and Aldh1A3 expression. Accordingly, 64 
only female Aldh1A1−/− mice resisted diet-induced visceral obesity and glucose intolerance seen in WT 65 
mice. The glucose intolerance was transiently reversed by intraperitoneal RA injections into Aldh1A1−/−  66 
females. 67 
Global proteomic comparison of WT and Aldh1A1−/− visceral fat revealed that Aldh1A1−/− mice 68 
had a subset of proteins changed in a sex-specific manner. Protein changes were mediated by 69 
mTORC1/p70S6K inhibition in Aldh1A1−/− females only. In consonance with mTORC1 inhibition, 70 
female, but not male Aldh1A1−/− mice had increased thermogenesis. Mechanistic studies demonstrated 71 
that RA activated and Rald inhibited mTORC1/p70S6K activation. 72 
In the female model of visceral obesity induced by ovariectomy, Aldh1A1 deficiency also 73 
suppressed RA generation, inhibited mTORC1/p70S6K, and prevented visceral obesity. Similar 74 
mechanisms may be at work in women, who abundantly express Aldh1A1 in visceral adipocytes. Our 75 
data suggest a novel signaling role for Rald and RA in the regulation of sex-specific metabolic 76 
differences, and propose Aldh1A1 as a candidate target for treatment of visceral obesity in women.  77 
 78 
 79 
 80 
 81 
 5
INTRODUCTION 82 
The female “thrifty” metabolism offered an evolutionary advantage during starvation. However, on a 83 
Western diet or after menopause, visceral obesity is prevalent in women (61.3% vs. 42%, in men) and 84 
increases their risks for type 2 diabetes, cardiovascular disease, cancer, and premature death (1-4). 85 
Visceral obesity is a polygenic and multifactorial disorder that is predisposed to by many systemic 86 
factors, including sex hormones (5). The preferential distribution of fat to visceral depots is characteristic 87 
of males; How a high-fat diet and decreased estrogen levels during the postmenopausal period promote 88 
visceral obesity in females is poorly understood (5, 6). 89 
 90 
Vitamin A (retinol/ retinyl esters) and its metabolites regulate cell differentiation and metabolism through 91 
transcriptional mechanisms that involve specific nuclear receptors and various transcription factors (7-92 
10). These functions are mediated by the three major vitamin A metabolites:  retinol, retinaldehyde 93 
(Rald), and retinoic acid (RA) (9, 10). Less is known about the non-genomic role of retinoids (10). A 94 
recent report shows that stimulation of neurons with RA leads to rapid activation of the mammalian target 95 
of rapamycin (mTOR) (11), a serine/threonine protein kinase implicated in insulin signaling and 96 
regulation of translation by phosphorylation of p70S6 kinase and elongation factor binding protein (4E-97 
BP1) (12). mTOR exists as two structurally and functionally distinct multiprotein complexes: rapamycin-98 
sensitive mTORC1 and rapamycin-insensitive mTORC2. mTORC1 is also a well-established nutrient 99 
sensor that plays a key role in adipogenesis and diet-induced fat formation in rodents (13-15) and humans 100 
(16). Whether vitamin A metabolites regulate mTORC1 activation in obesity remains unknown. 101 
 102 
Retinoid production and catabolism are controlled by different families of enzymes and binding proteins, 103 
which have distinct expression patterns in different tissues (8, 17). Rald is generated from retinol by 104 
alcohol dehydrogenases (Adh) and retinol dehydrogenases (Rdh). RA is produced solely from Rald by the 105 
cytosolic aldehyde dehydrogenase-1 family of enzymes (Aldh1 also known as Raldh). The expression of 106 
vitamin A-metabolizing enzymes is under spatiotemporal endocrine control including influences by sex 107 
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hormones (8). Estrogen suppresses Aldh1A1 and increases Aldh1A2 expression in the uterus (18, 19); 108 
dihydrotestosterone and RA activate Aldh1A3 expression (20). These Aldh1 enzymes may control 109 
equilibrium between Rald and RA. In pharmacological treatment with retinoids, both Rald and RA 110 
regulate adipogenesis and fat formation (21-24). Altered vitamin A homeostasis can also have a marked 111 
impact on the development of obesity (23, 25-27). Deficiency in Rald-generating enzymes facilitates diet- 112 
induced obesity (25, 26). In contrast, increased Rald levels in Aldh1A1−/− mice render them resistant to 113 
diet-induced obesity (23). Numerous and somewhat controversial data in diet-induced obesity models, 114 
leave many questions unanswered regarding the role of vitamin A metabolism in the regulation of fat 115 
distribution between subcutaneous and visceral depots or sex-specific effects in adipose tissue.  116 
Here, we provide evidence that sex-specific expression of the Aldh1 enzymes alters RA generation, 117 
thereby orchestrating visceral fat formation in a sex-specific manner. 118 
 119 
RESULTS 120 
Aldh1A1 deficiency results in sex-specific formation of visceral fat 121 
To test whether Aldh1A1 influences sex-specific differences in fat formation we analyzed WT and 122 
Aldh1A1−/− male and female mice on regular chow and after 180 or 300 days on a high-fat diet (Figure 123 
1A). Both WT and Aldh1A1−/− female mice weighed less than male mice on a regular chow diet. On a 124 
high-fat diet, WT females and males had similar weight. Food and water intake was similar between 125 
males and females of both genotypes on a high-fat diet (Figure 1B). WT females, however, accumulated 126 
more fat than WT males, specifically in visceral (perigonadal) depots (Figure 1C, D;). The Aldh1A1−/− 127 
female mice gained significantly less weight than males due to marked suppression of visceral fat 128 
formation (Figure 1A, D; Supplementary Figure 1A, B). The longer HF feeding (180 vs.300 days) 129 
further suppressed visceral depot mass in Aldh1A1−/− mice and this proceeded in sex-specific fashion 130 
(Figure 1, A, D; Supplementary Figure 1B). The increase in visceral fat on a high-fat diet was 131 
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associated with large adipocytes in all groups, with the exception of Aldh1A1−/− females, which 132 
maintained small adipocyte size (Figure 1D). The Aldh1A1−/− females were also significantly more 133 
glucose tolerant than Aldh1A1−/− male mice (Figure 1E). Thus, diet-induced fat formation in Aldh1A1−/− 134 
mice was impaired in a sex-specific fashion, namely, female mice resisted visceral obesity more than 135 
male mice.  136 
Aldh1A1 deficiency impairs RA generation in female but not in male mice 137 
Given the known role of Aldh1A1 in RA production from Rald (23, 28), we examined whether Aldh1A1 138 
deficiency influences the expression of vitamin A metabolizing enzymes in visceral fat (Figure 2A). WT 139 
males and females had similar expression of Rald-generating Adh enzymes (Figure 2B, left panel). In 140 
Aldh1A1−/− mice, the expression of Adh enzymes in visceral fat was not altered compared to WT mice, 141 
with the exception of decreased expression of Adh3 in Aldh1A1−/− males.  Overall Adh3 expression was 142 
relatively low compared to the abundant Adh1 enzyme. Expression of Rdh10 and Rdh1 as well as 143 
Aldh8a1 enzymes did not differ between groups (Fig. 2B and Supplementary Figure 1B,C). Short-chain 144 
dehydrogenase/reductase and aldo-keto reductase enzymes were not examined in this study. 145 
In contrast to similarly expressed Adh enzymes, RA-generating enzymes from the Aldh1 family had 146 
markedly different expression in WT males and females, which was especially evident in Aldh1A1−/−  147 
mice (Figure 2B, right panel). Aldh1A1 was expressed at higher levels than the other Aldh1 enzymes in 148 
visceral fat of WT male and female mice. Aldh1A2 and Aldh1A3 expression was lower in WT females 149 
than in WT males. Both Aldh1A2 and Aldh1A3 expression were lower in Aldh1A1−/−  females than in 150 
males, with Aldh1A1−/−  females having the lowest expression of RA-generating Aldh1 enzymes. 151 
Consistent with this, expression of the RA receptor target gene Cyp26A1 was significantly lower in 152 
Aldh1A1−/− females compared to WT females (6.6% vs.100%) (Figure 2C). Cyp26B1 was expressed at 153 
similar levels in all groups (Figure 2C). We also examined differences in RA production in visceral fat, 154 
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using cell lines that expressed a luciferase reporter construct containing RA response element (RARE) 155 
(Figure 2D).  In consonance with known selective activation of RARE by retinoic acid (9), in our assay, 156 
RARE activation induced by Rald was 100 times lower than that of RA (based on EC50), in keeping with 157 
prior data in transiently transfected cells (29). To investigate whether decreased expression of Aldh1 158 
enzymes in Aldh1A1−/−  female mice is associated with decreased RA production, we extracted lipophilic 159 
compounds from visceral fat and stimulated RARE-expressing cells with these extracts. The validation of 160 
the RARE assay and plasma retinol concentrations are shown in Supplementary Figure 2A, B. The 161 
lowest RARE reporter activity was associated with lipid extracts from visceral fat of Aldh1A1−/− females 162 
(81% compared to RARE activation from WT females) (Figure 2E).  163 
To show that such a moderate decrease in RA concentrations has an impact on metabolic processes in 164 
Aldh1A1−/− females, RA was injected intraperitoneally into the Aldh1A1−/− females  followed by a glucose 165 
tolerance test 10 min after injection (Figure 2F, left panel). The treatment with RA in the Aldh1A1−/−  166 
females was sufficient to significantly impair glucose tolerance compared to Aldh1A1−/− females injected 167 
with vehicle. Nonetheless, even in the presence of RA, AldhAa1−/− remain more glucose tolerant than WT 168 
females. To support the presence of RA in circulation 10min after its intraperitoneal injection we 169 
stimulated RARE-expressing cells by plasma of RA- and mock-injected mice (Supplementary Figure 170 
2C). The RARE was significantly activated by plasma of RA-, but not mock-injected animals. In contrast, 171 
intraperitoneal injection of Rald to WT females partially improved glucose tolerance in these animals 172 
(Figure 2F, right panel). 173 
 Aldh1A1 deficiency results in sex-specific changes in proteins in visceral fat  174 
To define mechanisms by which sex- specific production of RA in Aldh1A1−/− mice influences visceral 175 
fat, we performed a comparative proteomic analysis of visceral fat in WT versus Aldh1A1−/− mice in male 176 
and female groups (Supplementary Figure 3). DIGE analysis of the proteome revealed 13 proteins that 177 
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varied significantly in abundance in visceral fat from WT versus Aldh1A1−/− mice after false discovery 178 
rate correction (FDRC) of 176 and 167 proteins in male and female groups that were different between 179 
WT and Aldh1A1−/− mice without FDRC. Table 1 shows the proteins that changed significantly by DIGE 180 
analysis: 1) in both male and female groups (e.g. Group 1’Significant in both groups in proteomic 181 
analysis’); 2) only in male groups; and 3) only in female groups. Among identified proteins were Atgl, 182 
Serpina3a, a paralog of vaspin, and caspase1. Previous reports have implicated PPARγ, RXR or their 183 
ligands, such as glitazones and RA, in the regulation of these genes (30-33). We analyzed mRNA 184 
expression of all proteomic marker genes from Table1 (last four columns) and established genes related to 185 
PPARγ and RXR pathways (Fabp4 and leptin) in visceral fat from each mouse group (Supplementary 186 
Figure 4). Quantitative examination of mRNA expression of all proteomic markers showed significant 187 
differences in the expression of many genes in the WT and Aldh1a1−/− groups (Table 1, Group 3; 188 
Supplementary Fig. 4, caspase1). Three markers, Glod4, Tgh, and leptin, were differentially expressed in 189 
the female groups of WT and Aldh1A1−/− mice; Vaspin was differentially expressed in the WT and 190 
Aldh1A1−/− male groups. However, none of the proteomic markers was expressed in a sex-specific fashion 191 
in Aldh1A1−/− male and female groups. Thus, despite the significant differences in protein levels in 192 
visceral fat, the changes in mRNA expression of proteomic markers were not sex-specific within the 193 
Aldh1A1−/− group (Table 1, last column). Our subsequent experiments elucidated mechanisms that 194 
mediate sex-specific differences in protein, but not in mRNA expression in Aldh1A1−/− mice.  195 
Among proteins significantly changed in the female group in DIGE was a major adipose triglyceride 196 
lipase and PPARγ target gene, Atgl (30, 34). Quantitative analysis of visceral fat from the same mice 197 
revealed that Atgl mRNA expression in visceral fat was similar in all groups (Figure 3A), whereas Atgl 198 
protein levels were significantly higher in Aldh1A1−/− females compared to all other studied groups 199 
(Figure 3B). To examine whether this regulation pattern depends on the decreased RA generation from 200 
Rald seen in Aldh1A1−/− females, we stimulated differentiated 3T3-L1 adipocytes with retinoids (100nM) 201 
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(Figure 3C). We observed a significant increase in Atgl protein levels upon stimulation with Rald, 202 
whereas RA and retinol did not influence Atgl levels. A possibility that mTORC1, a known mediator of 203 
protein translation induced by nutrients (15, 35), can affect Atgl protein levels in adipocytes was tested in 204 
differentiated 3T3-L1 adipocytes treated with rapamycin (Figure 3D). Rapamycin increased Atgl protein 205 
levels in a dose-dependent manner (Figure 3D). The effect of RA and Rald on the activation of mTORC1 206 
was further examined in HEK293 cells (Figure 3E). RA stimulation (100nM) significantly increased 207 
insulin-mediated phosphorylation of p70S6K, an mTORC1 downstream target. In contrast, the same Rald 208 
concentration suppressed this effect in HEK293 cells (38.9% vs. 100% in cells stimulated with insulin 209 
alone). 210 
Aldh1A1 deficiency suppresses mTORC1 activation in vitro and in vivo 211 
Next, we elucidated the putative link between vitamin A metabolism and mTORC1 regulation in vitro in 212 
differentiated 3T3-L1 adipocytes. Among Rald-generating enzymes, Adh1 (306%) and Adh3 (143%) were 213 
expressed at higher levels in differentiated versus non-differentiated pre-adipocytes (Figure 4A). Rdh10 214 
expression was lower in differentiated (59%) than in non-differentiated pre-adipocytes; Rdh1 and Adh4 215 
expression was very low and did not change during differentiation. Among RA-generating enzymes, 216 
Aldh1A1 was the only enzyme induced significantly during differentiation (201%, P<0.035); moreover, 217 
Aldh1A1 had the highest expression level among Aldh1 enzymes (Figure 4B). The mitochondrial Aldh2 218 
and Aldh8A1 are inefficient at Rald oxidation and were not studied here (8). Since Aldh1A1 was the most 219 
highly expressed RA-generating enzyme, we compared RARE activation during the course of 220 
differentiation in WT and Aldh1A1−/− fibroblasts permanently transfected with a RARE- luciferase 221 
reporter (Figure 4C). Differentiation in WT fibroblasts was accompanied by RARE activation, whereas 222 
during differentiation of Aldh1A1−/− adipocytes, RARE activation was markedly reduced as compared to 223 
WT adipocytes (64% reduction at day 7). The decreased RARE activation was consistent with the 224 
absence of Aldh1A1, the low expression levels of other Aldh1 enzymes, and impaired differentiation that 225 
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manifested as higher expression ratio of preadipocyte marker Pref1 to adipocyte differentiation marker 226 
Fabp4 (Supplementary Figure 5). To establish a link between decreased RA generation in Aldh1A1 227 
deficiency and mTORC1 regulation, WT and Aldh1A1−/− adipocytes were stimulated with insulin with or 228 
without rapamycin.  The insulin treatment increased p70S6K phosphorylation, which was inhibited by 229 
rapamycin in WT adipocytes, but in Aldh1A1−/− adipocytes insulin and rapamycin did not have influence 230 
the levels of phosphorylated p70S6K (Figure 4D). In differentiated 3T3-L1 adipocytes, both rapamycin 231 
and Rald suppressed insulin-mediated phosphorylation of p70S6K (Supplementary Figure 5B). RA 232 
supports p70S6K phosphorylation in WT and 3T3-L1 adipocytes, while rapamycin abolished RA-233 
mediated p70S6K phosphorylation (Supplementary Figure 4C).  234 
In our RARE assay, Aldh1A1 deficiency manifested as reduced RA generation in visceral fat from female, 235 
but not male mice in vivo (Figure 2E). Consistent with the changes in RA metabolism, we found 236 
significantly reduced p70S6K phosphorylation only in Aldh1A1−/− females (Figure 4E). Of note, these 237 
differences were seen in starved (18h) mice without insulin treatment, and thus represent ‘basal’ 238 
differences in mTORC1 activation. Previous genetic studies in mice with disrupted mTORC1 pathways 239 
highlighted increased thermogenesis as a key mechanism responsible for the resistance to diet-induced 240 
obesity seen in these mice (14, 36). We compared thermogenesis markers, such as uncoupling protein-1 241 
(Ucp1) between female and male Aldh1A1−/− mice (Figure 4F). In agreement with mTORC1 suppression 242 
in Aldh1A1−/− females, markedly higher Ucp1 mRNA expression and protein levels were observed in 243 
visceral fat from Aldh1A1−/− female compared to Aldh1A1−/− male mice. Consequently, body temperature 244 
was increased only in Aldh1A1−/− females compared to all other groups.  245 
Aldh1 enzymes regulate visceral fat formation in ovariectomized mice 246 
The female-specific expression of Aldh1 enzymes rises the question of whether vitamin A metabolism 247 
influences visceral fat formation induced by estrogen deficiency. A causal relationship between Aldh1A1 248 
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and female-specific visceral obesity was established in sham-operated and ovariectomized WT and 249 
Aldh1A1−/− mice on regular chow. Ovariectomy did not alter the expression of Rald-producing enzymes in 250 
visceral fat, with the exception of decreased Adh4 in the WT sham group compared to all other groups 251 
(Figure 5A, left panel). In contrast, RA-producing enzymes in visceral fat showed altered expression 252 
from ovariectomy. Ovariectomized WT females expressed elevated Aldh1A1 and significantly increased 253 
Aldh1A3 mRNA levels compared to WT sham-operated females (Figure 5A, right panel). Accordingly, 254 
expression of Cyp26A1 was higher in ovariectomized than in sham WT females (Figure 5A, insert). 255 
Aldh1A1 deficiency significantly decreased expression of both Aldh1A2 and Aldh1A3 in sham-operated 256 
Aldh1A1−/− compared to WT females. Ovariectomized Aldh1A1−/− females also expressed less Aldh1A3 257 
than ovariectomized WT mice.  258 
As in the diet-induced obesity model, the deficiency in RA-generating enzymes in Aldh1A1−/− 259 
ovariectomized females resulted in decreased phosphorylation of p70S6K and 4Ebp1 in Aldh1A1−/−  260 
compared to WT ovariectomized mice (Figure 5B). In consonance with the suppression of these 261 
mTORC1 downstream targets, Atgl had increased protein levels, but not mRNA expression levels in the 262 
visceral fat of Aldh1A1−/− versus WT ovariectomized mice (Figure 5C). The limited mTORC1 263 
suppression was evinced in the reduced fat formation in diet-induced obesity models. In fact, whereas WT 264 
females gained weight following ovariectomy as expected (Supplementary Figure 6A), ovariectomized 265 
Aldh1A1−/− females had similar weight gain to sham-operated females. Food intake was also lower in 266 
ovariectomized Aldh1A1−/− females (Supplementary Figure 6B). These differences in weight gain 267 
depend in part on changes in visceral fat mass. The ovariectomized WT females had significantly 268 
increased visceral fat mass compared to WT sham females (240%), whereas visceral fat mass in 269 
ovariectomized Aldh1A1−/− females remained identical to sham-operated females (Figure 5D). MRI scans 270 
revealed that Aldh1A1−/− females retained basal visceral fat, but did not develop visceral fat after 271 
ovariectomy (Figure 5E).  272 
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Visceral fat in women expresses Aldh1A1  273 
To gain insight into relevance of Aldh1A1 for visceral fat biology in women, we analyzed expression of 274 
Aldh1 enzymes in non-differentiated (nD) and differentiated primary visceral preadipocytes (Figure 6A). 275 
Differentiation of visceral preadipocytes was accompanied by markedly increased expression of Aldh1A1 276 
(238%), which was significantly higher than the increase in Aldh1A3 expression (153%). In non-277 
differentiated (nD) adipocytes, Aldh1A3 expression was higher than that of Aldh1a1 (3.8E-6±2.9E-6 vs. 278 
1.6E-7±2.5E-7 AU). Aldh1A2 expression was 10-times lower than Aldh1A1 expression and was further 279 
decreased during adipogenesis (57% compared to nD).  280 
We also analyzed visceral fat isolated from three overweight premenopausal women (Figure 6B). In 281 
women, Aldh1A1 mRNA expression was the most abundant among Aldh1 enzymes. Aldh1A1 expression 282 
was significantly higher than that of Aldh1A3. Thus, in both female humans and rodents, Aldh1A1 is an 283 
important enzyme in visceral fat whose expression is induced during adipogenesis.  284 
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DISCUSSION 285 
The etiology of visceral obesity is not fully understood, although it is clear that sex hormones govern fat 286 
distribution between subcutaneous and visceral depots (5). Here we show that the Aldh1A1 enzyme that 287 
generates RA is essential for the formation of visceral fat in female mice. Our conclusion is based on the 288 
comparison of WT and Aldh1A1−/−  responses to a high-fat diet and to estrogen deprivation induced by 289 
ovariectomy. Aldh1A1 deficiency was sufficient to nearly prevent visceral fat formation in these two 290 
models (Figures 1, 5). This response was sex-specific, as Aldh1A1−/−  and WT males developed similar 291 
amounts of visceral fat mass on a high-fat diet. Our finding in the Aldh1A1−/− mouse model appears 292 
relevant to humans, since Aldh1A1 was abundantly expressed in visceral fat of women in vivo and 293 
differentiated adipocytes in vitro (Figure 6).  Visceral obesity in humans increases their risks of premature 294 
death related to the development of type 2 diabetes, certain cancers, and cardiovascular disease (4, 5). 295 
Importantly, the changes in visceral fat formation in these mouse groups corresponded to changes in 296 
glucose tolerance; e.g., Aldh1A1−/− females were maintaining normal glucose levels compared to the other 297 
groups. Thus, the Aldh1A1−/−  model is potentially useful to study sex-specific metabolic responses 298 
associated with visceral obesity.  299 
 300 
The mechanism by which Aldh1a1 influences sex-specific differences in visceral fat depends on the RA 301 
that is generated by all Aldh1 enzymes. Aldh1A1 expression was similar in WT male and female mice 302 
(Figure 2). In contrast, Aldh1A2 and Aldh1A3, was lower in WT females than in WT males, leaving 303 
Aldh1A1 as the major enzyme for RA production in females. Aldh1A1 produces RA from Rald, and the 304 
absence of this enzyme shifts the equilibrium between Rald and RA towards increased Rald 305 
concentrations (23, 28, 37). Consequently, Aldh1A1−/−  females developed deficient RA production 306 
(Figure 2E), whereas Aldh1A1−/−  males maintained similar RA levels to WT mice. Studies in RARE-307 
reporter-containing adipocytes further highlight the impact of Aldh1A1 on RA production, which was 308 
decreased by 70% in Aldh1A1−/−  compared to WT adipocytes (Figure 4C). 309 
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 310 
The mechanism behind suppressed Aldh1A2 and Aldh1A3 expression in visceral fat is yet to be defined, 311 
although our ovariectomy study demonstrated a significant increase in Aldh1A3 expression in 312 
ovariectomized vs. sham-operated mice (Figure 5A). This suggests an estrogen/estrogen receptor-313 
dependent mechanism for Aldh1A3 regulation (Schematic), which is in line with the published reports 314 
about Aldh1A2 and Aldh1A3 regulation by estrogen and its nuclear receptor in other tissues (18, 19, 38). 315 
In RARE adipocyte cultures, estrogen stimulation also inhibited RARE activation in Aldh1A1−/− but not in 316 
WT adipocytes (data not shown). In the present study, we could not determine whether the sex-specific 317 
changes in RA production uniquely affect visceral adipose tissue. More probably, Aldh1A1 plays 318 
different roles in different tissues (8) and also in different fat depots. For example, in our studies, both 319 
Aldh1A1−/−  males and females developed less subcutaneous fat than the respective WT mice (data not 320 
shown). This sex-independent response was likely due to the transcriptional repression of PPARγ by Rald 321 
(23, 28, 37). In visceral fat, we propose a paradigm of tandem regulation of sex-specific vitamin A 322 
metabolism by the action of sex hormones on the enzymes controlling Rald and RA production. This sex-323 
specific production of RA can potentially take place in other tissues and during development. Future 324 
experiments need to examine whether increased RA generation accompanies visceral fat formation in 325 
women after menopause. 326 
 327 
In Aldh1A1−/− female mice, there was an apparent discrepancy between the modest 20% decrease in RA 328 
generation (Figure 2E) and the remarkable 80% decrease in visceral fat and glucose tolerance (Figure 1) 329 
compared to other mouse groups. To prove the concept that sex-specific metabolic changes depend on 330 
diminished RA production, we injected RA and measured glucose tolerance in Aldh1A1−/−  females 331 
(Figure 2F). When compared to Aldh1A1−/−  females injected with vehicle, RA-injected Aldh1A1−/−  332 
female mice were significantly more glucose tolerant (Figure 2F). Since RA injection could not abolish 333 
glucose tolerance in Aldh1A1−/−  females, it is plausible that glucose intolerance WT females also depends 334 
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on other mechanisms. The response to RA varies in different animal models and is difficult to compare 335 
due to diverse methods of RA administration. Recent studies showed that RA releasing pellets (RA 336 
concentration in plasma is unknown) in WT mice lead to a temporal weight loss (39). Similar weight loss 337 
was found with subcutaneous injections of RA (10-100mg/kg body weight) (40) whereas in the other 338 
studies oral administration (41) of release of RA from microspheres (6.5 ng RA/ml plasma) (42) did not 339 
influence weight in rats. Importantly, in humans one clinical manifestation of all-trans-RA treatment in 340 
acute promyelocytic leukemia patients is weight gain (43). Given that RA administration also causes sex-341 
specific metabolic responses (41), more studies are needed to dissect specific pathways accounting for the 342 
differences seen with RA treatments. In our studies, administration of RA impairs glucose tolerance in 343 
Aldh1A1−/−  females, suggesting that an Aldh1A1−/−  phenotype resulted, partially, from deficient RA 344 
generation in these females (Figure 2F, left panel). Vice versa, the treatment with Rald somewhat 345 
improved glucose intolerance in WT females even after 300 days on a HF diet (Figure 2F, right panel). 346 
Rapid response to RA (30min) was previously reported in neurons that develop dendritic protrusions after 347 
RA activation of MAPK and mTOR-dependent translation (11).  348 
 349 
To gain a global view of the mechanisms participating in sex-specific visceral fat growth, we performed a 350 
comparative proteomic analysis in WT and Aldh1A1−/−  male and female mice (Supplementary Figure 3). 351 
Together, proteomic and mRNA expression analysis (Table1), can provide comprehensive information 352 
about changes in protein modification, protein levels, and mRNA expression, thereby highlighting 353 
mechanisms responsible for sexual dimorphism in Aldh1A1−/−  visceral fat. These studies revealed that 354 
protein levels of 13 identified proteomic markers were changed in a sex-specific manner. Many 355 
differences in mRNA levels were seen between WT and Aldh1A1−/−  mice, but they occurred in a sex-356 
independent manner (Table 1). Of note, Aldh1A1 deficiency led to the expected decrease in mRNA 357 
expression of RA- and/or glitazone-responsive leptin, vaspin, and caspase 1 (Supplementary Figure 4) 358 
(30-33). Given that glitazones activate PPARγ-dependent transcription, this expression pattern is 359 
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consistent with the transcriptional roles of RA (9) and Rald (23). These observations imply transcriptional 360 
regulation of differences in WT and Aldh1A1−/−  fat formation, whereas non-genomic actions of vitamin A 361 
metabolites mediate, to some extent, the sex-specific effects in Aldh1A1−/−  visceral fat. 362 
 363 
Here, we studied the regulation of Atgl as a representative example of the sex-specific changes resulting 364 
from Aldh1A1 deficiency. Atgl is a recently discovered critical enzyme for triglyceride lipolysis in 365 
adipose tissue and the heart (34). Atgl’s link to vitamin A metabolism is examined here for the first time. 366 
Atgl mRNA expression was identical in all groups (Figure 3A). In contrast, Atgl protein levels were 367 
markedly higher in Aldh1A1−/−  females than males (Figure 3B). The proteomic data underscores the 368 
translational mechanisms as a possible mediator of female-specific differences resulting from decreased 369 
RA production from Rald. Previous publications demonstrated that Aldh1A1 deficiency decreased Rald 370 
catabolism to RA and increased Rald levels in Aldh1A1−/− adipose and other tissues (23, 28, 37). Our 371 
hypothesis that the Rald to RA ratio can directly influence translational responses was further examined 372 
in cultured adipocytes stimulated with RA or Rald. Whereas Rald increased Atgl protein levels rapidly 373 
(40 min), RA had no such effect (Figure 3C). The translation of many proteins in adipose tissue is under 374 
the control of mTORC1 kinase’s  phosphorylation of p70S6 kinase (35). Rapamycin acts solely through 375 
mTORC1 and is a first indicator of this pathway at work. In the presence of rapamycin, adipocytes 376 
produced increased Atgl protein (Figure 3D).  To test if retinoids exert their effects through mTORC1, we 377 
performed short-term stimulation of HEK293 cells with or without Rald and RA in the presence of insulin 378 
and subsequently analyzed these cells for p70S6K phosphorylation by mTORC1. While Rald acted in a 379 
rapamycin-like fashion, RA activated p70S6K phosphorylation in HEK293 cells and in adipocytes 380 
(Figure 3E). A recent study demonstrated that similar RA activation of mTORC1 occurs in neurons and is 381 
mediated by a cytosolic RAR receptor (25). Here we suggest a specific non-genomic action of Rald.  382 
 383 
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Additional evidence that the intrinsic ratio of Rald to RA in cells regulates mTORC1 activation was 384 
demonstrated in vitro in differentiated WT and Aldh1A1−/− adipocyte cultures and in vivo in WT and 385 
Aldh1A1−/− adipose tissue. Insulin stimulation activated p70S6K phosphorylation in WT adipocytes, but 386 
failed to activate this kinase in Aldh1A1−/−  adipocytes (Figure 4D and C). In Aldh1A1−/− visceral fat, RA 387 
generation was impaired in females (Figure 2E), and only females had significantly decreased p70S6K 388 
phosphorylation (Figure 4E). A decrease in mTORC1 activation in adipocytes can change multiple 389 
adipose tissue responses and glucose tolerance (14). The targeted disruption of the mTORC1 catalytic 390 
subunit, raptor, in adipose tissue renders these mice resistant to diet-induced obesity and glucose 391 
intolerance. This phenotype is a result of increased mRNA and protein levels of Ucp1, a key thermogenic 392 
protein (14), and phosphorylation of IRS1 (35). Notably, similar thermogenic changes, resistance to 393 
obesity, and insulin sensitivity also occur in p70S6K−/− mice and in WT mice treated with rapamycin (13, 394 
36). Aldh1A1 deficiency in mice decreases RA production and increases Rald levels only in females, 395 
resulting in sex-specific mTORC1 inhibition (Figure 4E). These effects were to some extent reversible, 396 
e.g. glucose tolerance was partially impaired with RA in Aldh1A1−/− females and Rald improved glucose 397 
intolerance in WT females (Figure 2F). In agreement with the mTORC1 mechanism of repression in 398 
Aldh1A1−/− females, all bona fide effects of mTORC1 inhibition were manifested in Aldh1A1−/−  female 399 
but not male mice, including increased Ucp1 expression and protein levels (Figure 4F), increased 400 
temperature, improved glucose tolerance, and resistance to diet-induced visceral obesity (Figure 1). The 401 
sex-specific increase in thermogenic proteins alone provides a reasonable explanation for the resistance to 402 
obesity seen in Aldh1A1−/−  female but not male mice. These in vivo data, combined with our previous in 403 
vitro observations, demonstrate that Rald and RA regulate mTORC1 in opposite fashions, with Rald 404 
inhibiting, and RA activating mTORC1. While the metabolic role of mTORC1 is just emerging, the role 405 
of mTORC1 in cancer and aging has been well documented (14, 35, 44). Remarkably, rapamycin 406 
treatment increased lifespan in female more than in male monkeys in the recent longevity study (44). 407 
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Thus, divergent regulation of mTORC1 by the endogenous metabolites, RA and Rald, and their 408 
converting enzymes could have wide implications in understanding tumorigenesis and aging.  409 
While our first study is aimed at defining a relevant mechanism for visceral fat inhibition in Aldh1A1−/−  410 
mice, many emerging questions remain unanswered: What leads to mTORC1 inhibition:  the deficiency 411 
in RA or the increase in Rald?; What protein in the mTORC1 signaling cascade is affected by retinoid 412 
production? The speculations could include cytosolic RAR interaction with RA proposed previously (11). 413 
RAR contains lysines in its ligand binding domain (45) ,and lysines bind aldehydes, such as Rald (46); 414 
however, this possible interaction needs to be addressed experimentally. To further establish the relevance 415 
of Aldh1A1 deficiency on mTORC1 inhibition and the relevance of this mechanism for visceral obesity, 416 
we turned to a female-specific visceral obesity model, namely ovariectomy- induced estrogen deprivation.  417 
Ovariectomized WT mice gain weight on regular chow, thereby minimizing the impact of oxidized lipids, 418 
which could serve as a substrate for the Aldh1A1 enzyme. Ovariectomy in WT females leads to modest 419 
up-regulation of one RA-generating enzyme, Aldh1A3; in Aldh1A1−/−  mice, however, the expression of all 420 
RA-generating enzymes was suppressed (Figure 5A). These changes in the vitamin A pathway result in 421 
significant suppression of mTORC1 downstream targets p70S6K and 4Ebp, and an increase in Atgl 422 
protein levels associated with this pathway (Figure 5B, C). Consequently, ovariectomy failed to induce 423 
visceral obesity in Aldh1A1−/−  females (Figure 5D, E). Similar to the diet-induced obesity model, in the 424 
ovariectomized model, Aldh1A1 was a critical mediator of visceral obesity that proceeded at least in part 425 
by mTORC1. Given the pluripotent effects of RA and Rald (8, 10), a variety of other not yet identified 426 
mechanisms could contribute to the Aldh1A1−/−  phenotype and the differences seen in diet- and 427 
ovariectomy-induced visceral fat formation. Of note, the basal levels of visceral fat that developed in WT 428 
and Aldh1A1−/−  mice on a regular chow were not markedly affected by Aldh1A1 deficiency (Figure 5E), 429 
suggesting Aldh1A1’s role in adaptive responses. The necessity of Aldh1A1 in the regulation of visceral 430 
obesity in response to dietary or hormonal stress makes this gene a candidate for anti-obesity therapy. 431 
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Aldh1A1 is expressed in adipose tissue in women (Figure 6); in the future, clinical studies should clarify 432 
whether this gene can serve as a therapeutic target for visceral obesity in women.  433 
Numerous clinical data suggest that metabolic disorders should be treated differently in men and women 434 
(3), which show the need for investigation of molecular mechanisms for sex-specific metabolic 435 
differences. Here, we demonstrate that a substantial part of visceral fat formation in females, but not 436 
males, depends on Aldh1A1. 437 
  438 
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MATERIALS AND METHODS 439 
 440 
Reagents: We purchased reagents from Sigma-Aldrich and cell culture media from Invitrogen unless 441 
otherwise indicated; antibodies to phosphop70s6 kinase (Thr389) (p70S6K_P) were from Millipore, to 442 
total p70S6K, Atgl, and Gapdh were from Cell Signaling Technology, to β-actin and tubulin were from 443 
Abcam; infrared labeled secondary antibodies were from LI-COR. We used all-trans retinoid isomers. 444 
We purchased the Cignal Lenti inducible RARE reporter vector from SABiosciences. 445 
Human subjects: mRNA was isolated from fat tissue, which was obtained from healthy women who 446 
underwent surgery as kidney donors and had given informed consent. The protocol was approved by the 447 
Mayo Clinic Institutional Review Board for Human Research. Subjects were 41 ± 2 yr of age. The 448 
subjects’ mean body mass index (BMI) was 30.3± 0.4 kg/m2 (more information in supplementary 449 
materials). Human primary preadipocytes were isolated from visceral fat as described in supplementary 450 
materials and were used for cell culture experiments. 451 
Animal studies: Generation and characterization of Aldh1A1−/− mice, including metabolic responses to a 452 
high-fat diet, have been previously described (8, 23, 47). All experimental protocols were approved by the 453 
Institutional Animal Care and Use Committee. 454 
I Diet-induced obesity study: Age-(8 weeks old) and sex-matched Aldh1A1−/− and WT mice (5 males, 5 455 
females per genotype) were fed either regular chow or a high-fat diet (HF, 45% fat/kcal with standard 456 
vitamin A content, 4IU/g, D12451, Research Diets Inc., Canada) for 180 days. This study was performed 457 
two times. Third study was performed identically, but mice were fed the same HF diet for 300 days 458 
(Aldh1A1−/−: 5 males and 10 females; WT: 4 males and 5 females). 459 
II Ovariectomy study: Seven-month-old WT and Aldh1A1−/− females were ovariectomized or sham-460 
operated (n=5 per genotype in each surgery group). 461 
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Weight and food consumption were measured weekly to monitor metabolic changes. Body composition 462 
was measured by dual-energy X-ray absorptiometry (DEXA) using a GE Lunar Corporation PIXImus2 463 
Dexa Scanner and normalized to a quality control plot (Charles River Laboratories). MRI of the 464 
intraperitoneal area was performed as described before (48) using a T1-weighted gradient-echo sequence 465 
on mice at the end of the study. Twenty-five contiguous, 1-mm thick axial GRE slices spanning the 466 
region from the superior pole of the uppermost kidney to the caudal aspect of each mouse were obtained 467 
using a spin-echo sequence with a 256 X 256 matrix size. Visceral (perigonadal) and subcutaneous fat 468 
pads were dissected and analyzed.  469 
Food and water intake were measured after mouse acclimation to a powdered HF diet (4 d) in metabolic 470 
cages (Ancare, Charles River Laboratories). Glucose tolerance tests (GTT) were performed in overnight 471 
fasted mice by intraperitoneal injection of a single 25% dextrose injection (0.004 ml/g body weight) using 472 
a glucometer for measurements (Accu-Chek Advantage, Roche or one Touch Ultra, LifeScan). Retinoic 473 
acid (0.1% 500nM concentration in ethanol) was injected in 1mL PBS, while 0.1% ethanol in 1mL PBS 474 
was injected to control animals 10 min prior to standard GTT. 475 
Lipid extraction. We dissected adipose tissue (~100mg) into tubes containing 200uL RIPA buffer with 476 
20µM EDTA under an argon atmosphere in the dark. Samples were immediately homogenized. One 477 
aliquot (20 µl) of sample homogenate was used to measure protein concentration. Another aliquot 478 
(100µL) of tissue homogenate was mixed with 100µl of PBS containing ~20µM EDTA, and, 479 
subsequently with 200µL of ethanol. More argon was added to prevent oxidation, then 4ml n-hexane was 480 
added and vortexed for 1min.  The lipophilic phase was separated by centrifugation, transferred into a 481 
new argon-containing tube, and dried under nitrogen. Lipid extracts were re-suspended in absolute 482 
ethanol to have identical protein concentrations (5µg protein/50µL ethanol). This entire procedure was 483 
carried out at 4°C in the dark. RARE containing cells (see ‘Transfection’) were stimulated with lipid 484 
extract solution (0.1%) in DMEM medium containing 1% delipidated serum in the dark. For recovery 485 
measurements, adipose tissue homogenate was substituted with 100nM RA and underwent similar 486 
extraction.  487 
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Cell culture: Murine 3T3-L1 preadipocytes were cultured, maintained, and differentiated using standard 488 
procedures (23, 49). Preadipocyte cell lines were derived from embryos of WT (FWT) and Aldh1A1−/− 489 
(FAldh1A1KO) as previously described (23, 49). In all preadipocyte cultures, differentiation was induced (day 490 
0) with a standard differentiation mixture of 3-isobutyl-1-methylxanthine (0.5mM), dexamethasone 491 
(1μM), and insulin (1.7 μM) in DMEM containing 10% fetal bovine serum (FBS). For differentiation into 492 
adipocytes, cells were maintained for 7 days in DMEM medium containing 10% FBS and insulin (1.7 493 
μM), which was replaced every 48h. To produce mature adipocytes, 3T3-L1 preadipocytes were cultured 494 
from 7 to 12 days. Stimulation was performed in serum-free medium. Retinoids were protected from light 495 
throughout incubation and stored under an argon atmosphere. 496 
Human visceral (omental) preadipocytes were isolated from a female donor as described in 497 
Supplementary materials. Preadipocytes were differentiated as described previously (50) using  plating 498 
medium without serum supplemented with 100 nM dexamethasone, 500 nM human insulin, 200 pM 499 
triiodothryonine, 0.5 µM rosiglitazone, antibiotics, and 540 µM isobutylmethylxanthine (removed after 2 500 
days). Cells were differentiated for 21 days. Medium was changed weekly. 501 
 502 
Protein analysis and Proteomic 2-D Fluorescence Difference Gel Electrophoresis (DIGE): We 503 
prepared tissue homogenates and cell lysates in radioimmunoprecipitation assay buffer (RIPA) containing 504 
complete protease and phosphatase inhibitors with EDTA (Hoffman-LaRoche). Protein content was 505 
measured by Bicinchoninic acid protein assay (Thermo Fisher Scientific).  506 
Four homogenates from visceral fat each from males and females of WT and Aldh1A1−/− genotypes were 507 
precipitated with 10% trichloroacetic acid and used for DIGE (GE Healthcare) according to the 508 
manufacturer protocol (see Supplement Methods). Samples were labeled with DIGE fluor minimal-label 509 
dyes and focused on 18cm pH 4-7 Immobiline strips using an IPGphor II IEF. After SDS-PAGE, 510 
individual gels (containing one each of cy2, cy3, and cy5 images) were spot mapped using the Decyder 511 
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Differential image analysis module and analyzed by Decyder Biological Variation Analysis software 512 
using internal standard (cy2) images. Statistical analysis between WT and Aldh1A1−/− groups in males and 513 
females (P<0.05, independent t-test) was performed to identify spots with more than 1.5 fold differences 514 
in abundance, and spots appeared in at least 3 of the 4 gels. We identified 176 spots in male and 167 spots 515 
in female groups that were different between WT and Aldh1A1−/− mice without false discovery rate 516 
correction (FDRC). Only 13 proteins that were significantly different between WT and Aldh1A1−/− mice 517 
after FDRC analysis were spotted and identified. We define them as proteomic markers in this paper. 518 
Significantly changed spots were matched between analytical gels and preparative gels, and then cored 519 
from preparative gels using an Ettan workstation. We identified extracted peptides using a capillary liquid 520 
chromatography system equipped with a LTQ mass spectrometer (MS) detector (CCIC MS and 521 
Proteomics facility, the Ohio State University Medical Center). MS data was searched using Mascot 522 
(scores of >40 were accepted). Expression of proteomic markers was further verified using Western blot 523 
or TaqMan analysis of mRNA expression using visceral fat from the same mice. 524 
For Western blot analyses, cell or tissue lysates were separated on 10% acrylamide gel under reducing 525 
conditions. After transfer to a polyvinylidene fluoride membrane (Immobilon-P, Millipore), proteins were 526 
analyzed using an Odyssey Infrared Imaging System (LI-COR).  527 
 528 
Histology: We embedded adipose tissue in paraffin before hematoxylin and eosin (H&E) staining 529 
followed by quantification of adipocyte size (ImageJ software). 530 
 531 
Analysis of mRNA: mRNA was isolated from adipose tissue and adipocyte cultures according to 532 
manufacturer’s instructions (Qiagen). For semi-quantitative analysis of expression, cDNA was prepared 533 
from purified mRNA and analyzed using 7900HT Fast Real-Time PCR System and TaqMan fluorogenic 534 
detection system (Applied Biosystems). Validated primers were also purchased from Applied Biosystems. 535 
Reference sequences, gene names, and aliases are described in Supplementary Table 1. Comparative 536 
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real-time PCR was performed in triplicate, including no-template controls. The mRNA expression of the 537 
genes of interest was compared to 18S expression levels. Relative expression was calculated using the 538 
comparative Ct method.  539 
Transfection studies: We derived stably transfected 3T3L1, WT (FWT), and Aldh1A1−/− (FAldh1A1KO) 540 
according to manufacturer instructions (SA Bioscience).  Briefly, after reaching 70% confluence cells 541 
were transfected with Cignal Lenti RARE-LUC reporter suspension (25 MOI/104 cells) in the presence of 542 
Polybrene (Millipore) transduction reagent in serum free MEM-medium. After 3hrs, cells were 543 
supplemented with 10% heatinactivated calf serum. Stable clones were selected and derived from the 544 
single cells selected by puromycin (0.75-1.5mg/mL, Invitrogen).  We measured luciferase activity using a 545 
dual-luciferase reporter assay (Promega). 546 
Statistical analysis: Data are shown as mean±SD or mean±SE of experiments which were performed at 547 
least in triplicate. Group comparisons were performed using Mann Whitney U test unless otherwise 548 
indicated, and correlations were examined by Pearson test.  549 
  550 
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Table 1.  Proteomic and semi-quantitative expression analysis (QPCR) of visceral fat from WT and 716 
Aldh1A1−/− male and female mice 717 
Difference in protein levels of proteomic markers measured in two groups:  1) male WT and Aldh1A1−/− 718 
mice and 2) female WT and Aldh1A1−/− mice using Proteomic 2-D Fluorescence Difference Gel 719 
Electrophoresis (DIGE) analysis (five left columns). An example of DIGE gels overlying labeled proteins 720 
in WT/KO male and female groups are shown in Supplementary Figure 3. Average ratio shows fold 721 
difference between genotypes. T-test (n=4). TaqMan analyses of mRNA expression of these proteins 722 
isolated from visceral fat of same animals in separate groups of 1) WT males; 2) WT males; 3) KO males; 723 
4) KO females (four right columns), Mann-Whitney U test (n=5). 724 
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FIGURE LEGENDS 726 
Figure 1.  Sexual dimorphism in visceral fat formation and glucose tolerance of WT and Aldh1A1−/− 727 
mice on a high-fat diet 728 
(A)  Whole body weight are shown in WT male (n=18) and female (n=17) mice on regular chow; in WT 729 
male (n=8) and female (n=9) mice on a high-fat diet (HF) for 180 days; in Aldh1A1−/− males (n=18) on 730 
regular, and (n=9, 180d and n=5, 300d) on HF and females (n=23) on regular, and (n=11;180d and n=7; 731 
300d) on HF. 300 days of diet did not significantly increase weight in WT mice (bars are not shown, 732 
62.6±4.2 males, 52.5±8.9 females). *, P<0.05 differences between genotypes; S, P<0.05 differences 733 
between sexes within one genotype. All Mann-Whitney U test. All data are shown as mean±SD.  734 
 735 
(B) Water and food consumption measured in metabolic cages in mice after HF feeding for 180 days (WT 736 
(all n=5); Aldh1A1−/− males (n=5) and females, n=5). Data are shown as mean±SD. 737 
 Food consumption was measured every week; it did not differ significantly between groups throughout 738 
HF feeding (data not shown). 739 
 740 
(C) White fat (inguinal and visceral (perigonadal)) weight in WT male and female (all, n=5) as well as in 741 
Aldh1A1−/− male and female (both, n=4) after 180 and 300 days (KO: male n=5, female n=7) on the HF 742 
diet. White fat mass in WT mice after 300d on HF diet was similar to those after 180d (4548.4±2341.9 743 
males, 9544.8±2135.7 females). DEXA measurements of fat (%) show similar results (Supplementary 744 
Figure 1A). Data are shown as mean±SD. *, P<0.05 differences between genotypes; S, P<0.05 745 
differences between sexes within one genotype.  746 
 747 
(D) Visceral fat weight in same groups of animals as in (C). Visceral fat mass in WT was after 300d on 748 
HF diet similar to those after 180d (3032.5±2307.1 males, 5861.3±1767.6 females). Inserts shows 749 
representative visceral fat pads from each animal group (180d on HF diet). Mean±SD. *, P<0.05 750 
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differences between genotypes; S, P<0.05 differences between sexes within one genotype. Individual 751 
differences in visceral fat of Aldh1A1−/− male and female mice are shown in Supplementary Figure 1B. 752 
 753 
(E)  Adipocyte size was calculated based on H&E sections of visceral fat from WT and Aldh1A1−/− mice. 754 
Representative sections are shown in an insert. *, P<0.05 (n=3, mean±SD).  755 
 756 
(F)  Glucose tolerance test in WT (open symbols, dashed lines) and Aldh1A1−/− (black symbols, solid 757 
lines) males (triangles) and females (circles) on a high-fat diet (all n=4, all animals were 180 days on HF 758 
diet from study described in A-E). *, P<0.05 differences between genotypes; S, P<0.05 differences 759 
between sexes within one genotype. All data are shown as mean±SD. 760 
 761 
Figure 2.  RA generation in visceral fat of WT and Aldh1A1−/− mice is sex-specific and influences 762 
glucose tolerance  763 
(A)  Schematics of the major enzymes participating in vitamin A metabolism. Rald is generated from 764 
retinol by alcohol dehydrogenases (Adh1, Adh3, and Adh4) and retinol dehydrogenases (Rdh1 and 765 
Rdh10) that are members of short-chain dehydrogenase/reductase (Sdr) family. Other 15 Sdr members of 766 
this family have reduced activity towards all-trans retinol isomers and are not studied here (reviewed in 767 
(51)). RA is produced solely from Rald by the cytosolic aldehyde dehydrogenase-1 family of enzymes 768 
(Aldh1A1, Aldh1A2, and Aldh1A3). This family is also known and retinaldehyde dehydrogenases family 769 
Raldh1, Raldh2, and Raldh3). Excess RA is oxidized by Cyp26A1 and, primarily, by Cyp26B1.  770 
 771 
 (B)  Relative expression of Rald-generating (left panel), RA-generating (right panel), and (C) RA-772 
catabolizing enzymes in visceral fat isolated from WT male (n=5), WT female (n=4), and Aldh1A1−/− 773 
male and female mice (both n=4) on a high-fat diet. All data are shown as mean±SE. 774 
 775 
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(D) Luciferase reporter assays with RARE in an Aldh1A1−/− fibroblast cell line stimulated with RA (open 776 
circles) or Rald (closed circles). All data are shown as mean±SD. 777 
 778 
(E)  RARE reporter assay using lipid extracts from visceral fat of WT and Aldh1A1−/− male and female 779 
mice on a high-fat diet (mean±SE, all n=5). *, P<0.025, Kendall’s W test. 780 
 781 
(F)  Left panel : Glucose tolerance test (GTT) in WT female mice with and without Rald (all on HF for 782 
390 days). Rald (1µM/1 mL PBS) or vehicle ( veh, 0.01% ethanol in 1mLPBS) were injected 783 
intraperitonelly, then with GTT test was performed. *, P<0.05 differences between vehicle and Rald 784 
treatments. The weight of WT female mice (mean±SD, n=4) in ‘veh’ and ‘Rald’ group was 52.9±8.2 and 785 
53.1±6.7, respectively. 786 
Right panel:  Glucose tolerance test (GTT) in WT (white circles) and Aldh1A1−/−  (black circles) female 787 
mice with (solid line)  and without RA (dashed line). All mice were on HF diet for ~300days. The weight 788 
of WT female mice (mean±SD, n=4, both ‘veh’ and ‘RA’ groups) was 44.0±4.6; in Aldh1A1−/− female 789 
mice (mean±SD, n=3, both ‘veh’ and ‘RA’ groups) was 26.9±2.6. RA (500nM/1 mL PBS) or vehicle 790 
(veh, 0.01% ethanol in 1mL PBS) were injected intraperitonelly, after 10minutes GTT test was 791 
performed. *, P<0.05 differences between vehicle and RA treatments in Aldh1A1−/− female mice; # 792 
P<0.05 differences between WT and Aldh1A1−/−  groups, Mann-Whitney U test. 793 
 794 
Figure 3.  Disparate effects of Rald and RA in the regulation of Atgl and the mTORC1 downstream 795 
target p70S6K 796 
(A)  Atgl mRNA expression measured by TaqMan and (B) protein levels measured by western blot were 797 
analyzed in visceral fat from WT and Aldh1A1−/− male and female mice (all mean±SD, n=4) on a high-fat 798 
diet. Insert shows Atgl protein levels in 3 animals from each group. 799 
 800 
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(C) Atgl levels in differentiated (8d) 3T3-L1 fibroblasts measured by western blot. Cells were stimulated 801 
for 45min with retinol (ROL), RA, and Rald (all 100nM) in 100nM insulin/20%FBS medium. Atgl levels 802 
were normalized to tubulin. Data are shown as a percent of vehicle control. Insert on the right shows a 803 
representative example of a western blot. *, difference between control (Veh) and Rald-stimulated cells; 804 
#, difference between Rald- and RA-stimulated cells, both P<0.05 (mean±SE, n=3).  805 
 806 
(D) Atgl levels in differentiated (8d) 3T3-L1 fibroblasts that were stimulated with indicated 807 
concentrations of rapamycin for 70min. 808 
 809 
(E)  Phosphorylated (S6K_P, gray bars) and non-phosphorylated p70S6 (white bars) kinase levels in 810 
HEK293 cells measured by western blot. Cells were deprived from serum for 18h then stimulated with 811 
100nM insulin/20%FBS (ins, 30min) with or without rapamycin (rapa), RA, and Rald (all 100nM, added 812 
10min after insulin). *, P<0.05 (n=3, mean±SD) (inserts shows a western blot example, S6K_P antibodies 813 
(Cell Signaling) typically recognize two bands in these cells). 814 
 815 
Figure 4.  Aldh1a1 deficiency decreases RA generation and suppresses mTOR/p70S6K in vitro and 816 
in vivo 817 
The expression of (A) Rald-generating and (B) RA-generating enzymes in non-differentiated (Non-D) 818 
and differentiated 3T3-L1 adipocytes. TaqMan expression data were normalized using 18S as an 819 
endogenous control. Relative expression was calculated based on the comparative Ct method. *, P<0.05 820 
(n=3, mean±SD).  821 
 822 
(C) RARE-WT and RARE-Aldh1A1−/− fibroblast lines were differentiated with a standard differentiation 823 
mix and measured for luciferase activity at different days of differentiation. Data were normalized to 824 
RARE activity seen in non-differentiated cells RARE-WT and RARE-Aldh1A1−/− fibroblast (nonD). *, 825 
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difference between RARE activity in non-differentiated (day 0) and differentiated adipocytes; #, 826 
difference between adipocytes of different genotypes, both P<0.05 (n=3, mean±SD). 827 
 828 
(D)  Phosphorylated (S6K_P) and total protein levels of p70S6 kinase (S6K) were measured in WT(FWT) 829 
and Aldh1A1−/− (FAldh1A1KO) differentiated fibroblasts (8d) stimulated with 100nM insulin/20%FBS with or 830 
without rapamycin (100nM) for 30min using western blotting. A representative example is shown in the 831 
insert. Protein levels were quantified and normalized to tubulin levels. *, P<0.05 (n=3, mean±SD) 832 
difference compared to insulin-stimulated FWT.  833 
 834 
(E)  Western blot analysis of S6K_P (left panel & insert of a western blot in two animals from each 835 
group), and p70S6 kinase (left panel & insert) levels in visceral fat from WT and Aldh1A1−/− male and 836 
female mice (all n=4, mean±SD) on a high-fat diet. Protein levels were normalized to Gapdh or tubulin 837 
for quantification. *, P<0.05 differences between genotypes; S, P<0.05 differences between sexes within 838 
one genotype. S6K_P antibody recognizes protein in insulin-stimulated control cell lysates.  839 
 840 
(F, left panel)  Ucp1 mRNA expression measured by TaqMan and (F, middle panel) protein levels 841 
measured by western blot were analyzed in the same visceral fat from WT and Aldh1A1−/− male and 842 
female mice as in (E). Insert shows a representative western blot from 2 animals from each group. BF- 843 
brown fat control lysates.  844 
(F, right panel) Rectal body temperature was measured in animals from the same study (n=5, mean±SD). 845 
*, P<0.05 differences between genotypes; S, P<0.05 differences between sexes within one genotype. 846 
 847 
Figure 5.  Aldh1A1 deficiency decreases expression of RA-generating enzymes, suppresses 848 
mTORC1, and prevents visceral fat formation induced by ovariectomy 849 
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(A, left panel, mean±SD) Relative expression of Rald-generating, RA-generating (A, right panel, 850 
mean±SE), and Cyp26A1 (A, insert, mean±SD) enzymes was measured in visceral fat isolated from 851 
sham-operated (n=5) and ovariectomized (OVX, n=4) WT and Aldh1A1−/− female mice on regular chow. 852 
#, P<0.05 differences between sham and ovariectomized; *, differences between ovariectomized WT and 853 
Aldh1A1−/− mice.  854 
 855 
(B) Western blot analysis of S6K_P and p70S6 kinase, 4Ebp1_P and total 4Ebp1, and (C, left panel) Atgl 856 
levels in WT and Aldh1A1−/− sham and ovariectomized female mice (all n=4, mean±SE). Insert shows a 857 
representative western blot in two ovariectomized WT and Aldh1A1−/− mice. Protein levels were 858 
normalized to β-actin. (C, right panel) Relative expression of Atgl in these mouse groups was normalized 859 
by 18S.  860 
 861 
(D) Weight of visceral fat pads and (E) cross-sectional MRI images in sham-operated (n=5) and 862 
ovariectomized (OVX, n=4) WT and Aldh1A1−/− female mice on regular chow. K, kidney; Vis, visceral 863 
fat; #, P<0.05 differences between sham and ovariectomized; *, differences between ovariectomized WT 864 
and Aldh1A1−/− mice. Data are shown as mean±SE. 865 
 866 
Figure 6.  Prevailing expression of Aldh1A1 in the course of visceral adipogenesis and in visceral fat 867 
in women 868 
(A) Relative changes in mRNA expression of Aldh1 enzymes in differentiated visceral (om, omental) 869 
adipocytes (21 d) compared to expression levels of each enzyme (100%) in non-differentiated 870 
preadipocytes (#, P<0.01 Mann- Whitney U test, mean±SD, n=3). The expression levels in non-871 
differentiated preadipocytes were 1.6E-7±2.5E-8 (Aldh1A1), 1.4E-8±3.8E-9 (Aldh1A2), and 3.8E-6±2.9E-872 
7 (Aldh1A3). 873 
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(B) mRNA expression (TaqMan) of Aldh1 enzymes in visceral adipose tissue isolated from three women. 874 
Relative expression of Aldh1 (mean±SD)  in these donors was normalized by 18S using ΔCt method. #, 875 
P<0.01, differences between expression of Aldh1A1 and other Aldh1 enzymes. 876 
 877 
Schematic 1.  Proposed model for regulation of visceral obesity in females:  simultaneous action of diet 878 
and estrogen regulates the expression of the Aldh1 family of enzymes. Generated Rald or RA regulates 879 
mTOR and influences translation of specific proteins including Atgl and Ucp1. The resulting changes in 880 
thermogenesis, lipolysis, and other aspects of adipocyte metabolism determine female susceptibility to 881 
visceral fat formation.  882 
  883 
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SUPPLEMENTAL  INFORMATION 884 
Figure S1. HF diet did not impair glucose tolerance test in Aldh1A1−/− mice; low mRNA expression 885 
levels of Rdh1 and Aldh8A1 in WT and Aldh1A1−/− mice on a HF diet 886 
(A) DEXA measurements of fat mass in mice after 180d on HF diet (n=5 in Aldh1A1−/− males WT males 887 
and females, n=4 in Aldh1A1−/− females). Individual values are shown as symbols: triangles,- males (WT 888 
white, Aldh1A1−/− males black);circles,-females (WT white, Aldh1A1−/− males black) *, P<0.05 889 
differences between genotypes; S, P<0.05 differences between sexes within one genotype. All data are 890 
shown as mean±SD. 891 
 892 
(B) Visceral fat weight in individual Aldh1A1−/−  males ( triangles, n=4 (180 d), n=5 (300d))  and females 893 
(circles, n=4 (180d) n=7 (300d)) on a high-fat diet  for 180 (white) and 300 days (gray). Lines show 894 
mean±SD in each group. *, P<0.05 differences between genotypes; S, differences between sexes within 895 
one genotype (P<0.008 (180d); P<0.028 (130d), both Mann-Whitney U test).  896 
 897 
(C) Relative mRNA expression of Rald reductase Rdh1 (left panel) and RA-generating Aldh1A8 (Raldh4) 898 
(D). Data are shown as individual values WT male (white triangles, n=5), WT female (n=4, white circles), 899 
and Aldh1A1−/− male and female mice (black triangles and circles, respectively, both n=4) on a high-fat 900 
diet (180days). TaqMan expression data were normalized to 18S expression. Values were not 901 
significantly different among groups (Mann-Whitney U test). 902 
 903 
 Figure S2. Validation of RARE assay by RA added in vitro and in vivo  904 
(A) Addition of RA(100nM) to the lipophilic extract (LEA) of visceral adipose tissue activated 905 
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 RARE-luceferase in a stably transfected fibroblast clone. All procedures were performed under argon 906 
atmosphere in the dark. Visceral adipose tissue was dissected from a WT male (on HF diet 180 days) and 907 
homogenized in RIPA buffer. Lipophilic extracts  (5µg protein/50mL ethanol) were prepared from 100µL 908 
of adipose tissue homogenate in the absence (LEA) and in the presence of RA(100nM) (LEA+RA), as 909 
well as with RA (RA, 100nM) extracted using similar procedure. Data were normalized to RARE 910 
luciferase activity seen in the non-treated cells. Data are shown as mean±SD of three independent 911 
experiments. *, P<0.05 compared to control, Mann-Whitney U test.  912 
(B) Retinol concentration in lipophilic extracts from plasma from WT male (n=5), WT female (n=4), and 913 
Aldh1A1−/− male and female mice (both n=4) measured using HPLC method as described in (23) and 914 
Supplementary materials. Values were not significantly different among groups (Mann-Whitney U test). 915 
(C) RARE activation by serum (% in culture medium) isolated from WT male mouse 10 minutes after 916 
intraperitoneal injection with 1mL PBS (white bar, 0.5% serum) and 1mL PBS containing 500nM RA ( 917 
black bars, 0.5 and 1% serum). For comparison cells also were treated with RAR ligand TTNPB (1nM). 918 
Data were normalized to RARE luciferase activity seen in the non-treated cells. Data are shown as 919 
mean±SD of three independent experiments. *, P<0.05 compared to control, Mann-Whitney U test. 920 
Figure S3. Representative DIGE gel image overlays for male WT and Aldh1A1−/− (labeled with cy3 921 
and cy5 dyes) proteins (left panel) as well as for female WT and Aldh1A1−/− (labeled with cy3 and 922 
cy5 dyes) proteins (right panel) 923 
Proteins were homogenate of visceral adipose tissue from a study described in Figure 1 (180d). Each 924 
DIGE gel was performed 4 times with different WT and Aldh1A1−/− male or female pair of mice. Arrow 925 
shows and example of a protein varied in male WT and Aldh1A1−/− pair, but is absent in a female pair.  926 
Statistical analysis (independent T- test) was performed to identify spots that were significantly (P<0.05, 927 
n=4) different between groups (WT and Aldh1A1−/−). Significant spots were further filtered to identify 928 
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spots with more than 1.5 fold differences in abundance, and spots appeared in at least 3 of the 4 gels. 176 929 
spots were different between WT and Aldh1A1−/− mice without FDRC in male and 167 spots in female 930 
groups. Only proteins that were significantly different between WT and Aldh1A1−/− mice after FDRC 931 
analysis were spotted and identified. We defined them as proteomic markers in this paper. Of note, that 932 
many proteomic markers were changed in both male and female groups (Table 1, Group 1). Some of 933 
proteomic markers were only significantly changed in males (Table 1, Group 2) or in females (Table 1, 934 
Group 3). 935 
Figure S4. mRNA expression levels of nuclear receptors (Pparγ, RXR), Pparγ target gene (Fabp4), 936 
genes activated by Pparγ ligands (vaspin, caspase-1) and or RA (leptin, caspase-1) in visceral fat of 937 
WT and Aldh1a1−/− mice. 938 
Data are shown as individual values WT male (white triangles, n=5), WT female (n=4, white circles), and 939 
Aldh1A1−/− (KO) male and female mice (black triangles and circles, respectively, both n=4) on a high-fat 940 
diet (180days). TaqMan expression data were normalized to 18S expression. *, values were significantly 941 
different between WT and KO male or female groups (Mann-Whitney U test). Changes between WT 942 
males and females as well between KO males and females were not statistically significant (Mann-943 
Whitney U test). 944 
Figure S5. Impaired differentiation in Aldh1A1−/− vs. WT adipocytes and the opposite effects of RA 945 
versus Rald and rapamycin effects on mTOR activation in cultured adipocytes 946 
(A) Differentiated (7d) Aldh1A1−/− vs. WT adipocytes were analyzed for mRNA expression of Fabp4 and 947 
Pref1 that are markers of differentiated and non-differentiated adipocytes, respectively. Data are shown as 948 
ratio of Pref1 to Fabp4 expression. Values are mean±SD of three independent experiments. *, P<0.05, 949 
Mann-Whitney U test. 950 
 951 
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(B-D) Representative western blots of S6K_P and p70S6 kinase levels in differentiated (5d) 3T3-L1 (B, 952 
C) and WT (D) fibroblasts stimulated with 100nM insulin/20%FBS (ins, 30min) with or without 953 
rapamycin (rapa), RA, and Rald (all 100nM, added 10min after ins). Prior to stimulation cells were 954 
starved. 955 
 956 
Figure S6. Aldh1A1−/− female mice resist weight gain induced by ovariectomy 957 
(A) Body weight and (B) food intake in sham-operated (n=5) and ovariectomized (OVX, n=4, mean±SE) 958 
WT and Aldh1A1−/− female mice on regular chow. # P<0.05 differences between sham and 959 
ovariectomized, * differences between ovariectomized WT and Aldh1A1−/− mice. 960 
 961 
METHODS  962 
Human subjects 963 
mRNA was isolated from visceral (omental) fat tissue, which was obtained from healthy women who 964 
underwent surgery as kidney donors and had given informed consent. The protocol was approved by the 965 
Mayo Clinic Institutional Review Board for Human Research. All subjects had fasted at least 12 h. 966 
Subjects were 41 ± 2 yr of age. The subjects’ mean body mass index (BMI) was 30.3± 0.4 kg/m2. 967 
Patients’ fasting plasma glucose concentrations did not exceed 120 mg/dL, they were not taking 968 
thiozolidinediones (glitazones) or steroids, and they had no reported malignancies. Abdominal 969 
subcutaneous (external to the fascia superficialis) and greater omental fat were obtained from each 970 
subject. 971 
Preadipocyte culture 972 
Fat tissue was minced and then digested in phosphate buffered saline (PBS) containing 1 mg/ml 973 
collagenase in a shaking water bath (37°C). Digests were filtered and centrifuged at 800 g for 10 min. The 974 
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digests were treated with an erythrocyte lysis buffer and then plated in alpha minimal essential medium 975 
(α-ΜΕΜ) supplemented with 10% bovine serum and antibiotics. To eliminate endothelial cell and 976 
macrophage contamination, the adherent preadipocytes were replated after 12 h at a density of 4 ± 104 977 
cells/cm2 in plating medium as described before (50). The absence of macrophages in subcultured 978 
preadipocytes was confirmed by absence of macrophage markers assayed by quantitative RT-PCR. 979 
Preadipocytes were differentiated as described previously (50) using  plating medium without serum 980 
supplemented with 100 nM dexamethasone, 500 nM human insulin, 200 pM triiodothyronine, 0.5 µM 981 
rosiglitazone, antibiotics, and 540 µM isobutylmethylxanthine (removed after 2 days). Cells were 982 
differentiated for 21days. Medium was changed weekly. 983 
Magnetic resonance imaging (MRI) 984 
MRI of intraperitoneal area was performed as described (48), using a Bruker 11.7T NMR system (Bruker 985 
Instruments) with a 11.7-T Bruker magnet and a 52mm internal diameter vertical bore (Bruker 986 
Instruments, Billerica, MA) (500 MHz/gradient strength of 300 gauss/cm). We measured fat 987 
accumulation with a T1-weighted gradient-echo sequence on mice at the end of the study. We obtained 988 
and analyzed twenty-five contiguous, 1-mm thick axial GRE slices spanning from the superior pole of the 989 
uppermost kidney to the caudal aspect of the mouse using a spin-echo sequence with a 256 X 256 matrix 990 
size (pixel size, 117 x117 x 1,000 µm3).  991 
Proteomic analysis  992 
Sample preparation 993 
Samples were resuspended in DIGE labeling buffer (30mM TRIS, 7M urea, 2M thiourea, 2% CHAPS, 994 
pH 8.5) and protein concentrations were measured by Bradford assay. For each of the experiments, 94μg 995 
per sample was used for DIGE labeling, with 62.66μg cy3 or cy5 labeled, and 31.34μg from each sample 996 
combined as an internal standard and labeled with cy2. Samples, labeled DIGEfluor minimal-label dyes, 997 
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were combined for appropriate gels and diluted with rehydration buffer (7M Urea, 2M thiourea, 4% 998 
CHAPS, 10mg/ml DTT, 1% pH 4-7 IPG buffer, 0.1% bromophenol blue). Samples were immediately 999 
used to rehydrate 18cm pH 4-7 Immobiline dry strip isoelectric focusing strips under mineral oil 1000 
overnight. Subsequently, the strips were focused using an IPGphor II IEF. Focus strips were equilibrated 1001 
in EQ buffer 1 (50mM tris pH 8.8, 6M urea, 30% glycerol, 0.1% bromophenol blue, 2% SDS, 65mM 1002 
DTT) for 15 minutes, followed by EQ buffer 2 (50mM tris pH 8.8, 6M urea, 30% glycerol, 0.1% 1003 
bromophenol blue, 2% SDS, 135mM iodoacetamide) for 15 minutes. Strips were immediately placed in 1004 
12% 20X24cm lab-cast gels, sealed in place using agarose, and run on a Dalt12 electrophoresis system 1005 
following standard protocols. Proteomic analysis as performed at CCIC Mass Spec and Proteomics 1006 
facility, the Ohio State University Medical Center. 1007 
After SDS-PAGE, gels were immediately scanned 3 times in a Typhoon using appropriate settings for 1008 
each DIGE fluorophor. DIGE images were loaded into Decyder 2D 6.5 for analysis. Individual gels 1009 
(containing 1 each of cy2, cy3, and cy5 images) were spot mapped using the Decyder Differential Image 1010 
Analysis Module. Dust and saturated spots were filtered out manually. All images from the experiment (4 1011 
sets each) were then loaded into the Decyder Biological Variation Analysis software and internal standard 1012 
(cy2) images were matched. Matching images were grouped accordingly. Statistical analysis (independent 1013 
T 1014 
test) was performed to identify spots that were significantly (P<0.05) different between groups (WT and 1015 
Aldh1A1−/−). Significant spots were further filtered to identify spots with more than 1.5 fold differences in 1016 
abundance, and spots appeared in at least 3 of the 4 gels. False discovery rate correction was applied to 1017 
identify further the most likely biologically significant differences. We identified 176 spots in male and 1018 
167 spots in female groups that were different between WT and Aldh1A1−/− mice without FDRC. Only 1019 
proteins that were significantly different between WT and Aldh1A1−/− mice after FDRC analysis were 1020 
spotted and identified. We defined them as proteomic markers in this paper. 1021 
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Significantly changed spots were matched between analytical gels and preparative gels, and then cored 1022 
from preparative gels using an Ettan Spot Handling Workstation 2.1. Spots were washed with water, dried 1023 
with acetonitrile, and digested with Trypsin overnight in a 96 well plate. Peptides were extracted with 1024 
50% acetonitrile/5% formic acid and concentrated.  1025 
 1026 
Mass Spectrometer LTQ 1027 
Samples were identified using capillary liquid-chromatography-nanospray tandem mass spectrometry 1028 
(Nano-LC/MS/MS), which was performed on a Thermo Finnigan LTQ mass spectrometer equipped with 1029 
a nanospray source operated in positive ion mode. The LC system was an UltiMate™ 3000 system from 1030 
Dionex (Sunnyvale, CA). Solvent A was water containing 50mM acetic acid and Solvent B was 1031 
acetonitrile.  5 microliters of each sample was first injected onto the µ-Precolumn Cartridge (Dionex, 1032 
Sunnyvale, CA) and washed with 50 mM acetic acid. The injector port was switched to inject and the 1033 
peptides were eluted off of the trap onto the column. A 5 cm 75 µm ID ProteoPep II C18 column (New 1034 
Objective, Inc. Woburn, MA) packed directly in the nanospray tip was used for chromatographic 1035 
separations. Peptides were eluted directly off the column into the LTQ system using a gradient of 2-80%B 1036 
over 45 minutes, with a flow rate of 300 nl/min. The total run time was 65 minutes. The MS/MS was 1037 
acquired according to standard conditions established in the lab. Briefly, a nanospray source operated 1038 
with a spray voltage of 3 KV and a capillary temperature of 200PoPC is used. The scan sequence of the 1039 
mass spectrometer was based on the TopTen™ method; the analysis was programmed for a full scan 1040 
recorded between 350 – 2000 Da, and a MS/MS scan to generate product ion spectra to determine amino 1041 
acid sequence in consecutive instrument scans of the ten most abundant peaks in the spectrum. The CID 1042 
fragmentation energy was set to 35%. Dynamic exclusion is enabled with a repeat count of 30 s, 1043 
exclusion duration of 350 s, and a low mass width of 0.5 Da and high mass width of 1.50 Da.   1044 
 1045 
Sequence information from the MS/MS data was processed by converting the raw data files into a merged 1046 
file (.mgf) using an inhouse program, RAW2MZXML_n_MGF_batch (merge.pl, a Perl script). The 1047 
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resulting mgf files were searched using Mascot Daemon by Matrix Science version 2.2.1 (Boston, MA) 1048 
and the database searched against the full SwissProt database version 54.1 (283454 sequences; 1049 
104030551 residues). The mass accuracy of the precursor ions was set to 2.0 Da given that the data were 1050 
acquired on an ion trap mass analyzer and the fragment mass accuracy was set to 0.5 Da. Considered 1051 
modifications (variable) were methionine oxidation and carbamidomethyl cysteine. Two missed 1052 
cleavages for the enzyme were permitted. Peptides with a score less than 20 were filtered and proteins 1053 
identified required bold red peptides. Protein identifications were checked manually and proteins with a 1054 
Mascot score of 50 or higher with a minimum of two unique peptides from one protein having a -b or -y 1055 
ion sequence tag of five residues or better were accepted. Peptide mass fingerprinting and quadruple time-1056 
of-flight tandem mass spectrometry showed that five proteins were present in two different modifications. 1057 
Although important, the modification phenomena are beyond the scope of this study and will not be 1058 
examined and verified here. Expression of proteomic markers was further verified using western blot or 1059 
TaqMan analysis of mRNA expression using visceral fat from the same mice. 1060 
High-performance liquid chromatography (HPLC) 1061 
All procedure were performed under argon or nitrogen; samples were protected from light.  Blood was 1062 
collected in the presence of 0.25µM EDTA by cardiac puncture. Plasma (200µL) was reduced in 1063 
hydroxylamine (1M in100 µL methanol) in PBS (400 µL) for 1h at room temperature. Then ethanol (400 1064 
µL) and hexane (4mL) was added and lipid fraction was extracted.  We evaporated the hexane phase 1065 
under nitrogen, then resuspended in ethanol. Retinol was eluted fromPecosphere-3 C18 0.46x8.3cm 1066 
cartridge column (Perkin-Elmer, Inc., Norwalk, CT) using a mobile phase containing acetonitrile 1067 
/tetrahydrofuran/water (solvent A, 50:20:30 v/v/v, solvent B 50:44:6 v/v/v) at 1mL/min flow. Retinol was 1068 
detected with a photodiode array detector (Waters 996)43.  We analyzed samples using an external 1069 
standard (500nM all-trans retinol, Sigma-Aldrich).  1070 
 1071 
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A
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R
etinaldehyde synthesis 
A
dh1
A
lcohol dehydrogenase-1
N
M
_007409.2
m
alcohol dehydrogenase 1 (class I), A
D
H
-A
A
, A
I194826, A
dh-1, A
dh-1-t, A
dh-1-t, A
dh-1e, A
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dh3-e
A
dh3
A
lcohol dehydrogenase 7 (class IV
)
N
M
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m
alcohol dehydrogenase 7 (class IV
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a polypeptide, A
dh3, A
I325182, A
dh-3, A
dh-3e, A
dh-3t, A
dh3-e, A
dh3-t, A
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A
dh4
A
lcohol dehydrogenase 4 (class II)
N
M
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m
alcohol dehydrogenase 4 (class II), pi polypeptide, A
dh2
R
dh1
A
etinol dehydrogenase 1 (all-trans)
N
M
_080436.3
m
retinol dehydrogenase 1 (all trans)
R
etinaldehyde catabolism
/ R
A
 synthesis 
A
ldh1a1
A
ldehyde dehydrogenase fam
ily 1, subfam
ily A
1
N
M
_013467.3
m
retinaldehyde dehydrogenase 1, A
ldh1A
1, A
hd-2, A
dh2, A
ldh1, A
ldh1a2,E
1, R
aldh1
A
ldh1a2
A
ldehyde dehydrogenase fam
ily 1, subfam
ily A
2
N
M
_009022.3
m
retinaldehyde dehydrogenase 2, A
ldh1A
2, A
V
116159, A
ldh1a7, R
A
LD
H
-2, R
aldh1, R
aldh2
A
ldh1a3
A
ldehyde dehydrogenase fam
ily 1, subfam
ily A
3
N
M
_053080.3
m
retinaldehyde dehydrogenase 3, A
ldh1A
3, A
LD
H
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A
LD
H
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aldh3
A
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A
ldehyde dehydrogenase 8 fam
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em
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m
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aldh4
A
ldh2
A
ldehyde dehydrogenase 2, m
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N
M
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m
A
hd-5, A
hd5
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A
-catabolism
 
C
yp26a1
C
ytochrom
e P
450, fam
ily 26, subfam
ily a, polypeptide 1
N
M
_007811.1
m
cytochrom
e P
450 26 retinoic acid A
1, retinoic acid hydrolase, R
A
H
, C
yp26, P
450R
A
, P
450R
A
I, M
G
C
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C
yp26b1
C
ytochrom
e P
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ily 26, subfam
ily b, polypeptide 1
N
M
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m
cytochrom
e P
450 26B
1, cytochrom
e P
450 26 retinoic acid B
1, retinoic acid B
1, retinoic acid hydroxylase, C
P
26, P
450R
A
I-2
P
roteom
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arkers 
P
npla2
P
atatin-like phospholipase dom
ain containing 2
N
M
_025802.2
m
adipose triglyceride lipase, desnutrin, transport-secretion protein, triglyceride hydrolase, adipose-specific tryglycerol lipase, A
tgl, TTS
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21R
ik, 111 0
B
ckdhb
B
ranched chain ketoacid dehydrogenase E
1, beta polypeptide, B
ckdhb
N
M
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m
2-oxoisovalerate dehydrogenase subunit beta, B
C
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D
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beta
B
pnt1
3'(2')-5'-bisphosphate nucleotidase 1
N
M
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m
B
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caspase 1
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